IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:	**ISPH-0743**
Inventors:	**Monia and Wyatt**
Serial No.:	**Not Yet Assigned**
Filing Date:	**Herewith**
Examiner:	**Not Yet Assigned**
Group Art Unit:	**Not Yet Assigned**
Title:	**Antisense Modulation of Inhibitor-Kappa B Kinase-Gamma Expression**

"Express Mail" Label No. **EV331020003US**
Date of Deposit **July 28, 2003**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Mail Stop Sequence, P. O. Box 1450, Alexandria, VA 22313-1450.

By _____
Typed Name: **Jane Massey Licata, Reg. No. 32,257**

Commissioner for Patents
Mail Stop Sequence
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

( ) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

( ) The fee of $**240.00** as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of $**130.00** as set forth in §1.17(I)(1).

( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

(XX) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. **09/972,607**, filed **October 6, 2001** for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata
Registration No. 32,257

Date: **July 28, 2003**

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

DOCKET NO.: ISPH-0753

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0753	Serial No. not yet assigned
	Applicant Brett P. Monia *et al.*	
	Filing Date herewith	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Aradhya *et al.*, *Atypical forms of incontinentia pigmenti in male individuals result from mutations of a cytosine tract in exon 10 of NEMO (IKK-gamma)*, *Am. J. Hum. Genet.*, **2001**, *68*:765-771
	AB	Chu *et al.*, *IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1*, *J. Biol. Chem.*, **1999**, *274*:15297-15300
	AC	Doffinger *et al.*, *X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling*, *Nat. Genet.*, **2001**, *27*:277-285
	AD	Jain *et al.*, *Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia*, *Nat. Immunol.*, **2001**, *2*:223-228
	AE	Jin *et al.*, *Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma*, *J. Biol. Chem.*, **1999**, *274*:17402-17405
	AF	Karin *et al.*, *The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling*, *Semin. Immunol.*, **2000**, *12*:85-98
	AG	Krappmann *et al.*, *The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component*, *J. Biol. Chem.*, **2000**, *275*:29779-29787
	AH	Li *et al.*, *Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis*, *Proc. Natl. Acad. Sci. U. S. A.*, **1999**, *96*:1042-1047
	AI	Lin *et al.*, *Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta*, *Mol. Cell Biol.*, **2000**, *20*:2933-2940

EXAMINER	**DATE CONSIDERED**

Form PTO-1449 Modified	Docket No. ISPH-0753	Serial No. **not yet assigned**
List of Patents and Publications Cited by Application (Use several sheets if necessary)	Applicant Brett P. Monia *et al.*	
U.S. Department of Commerce Patent and Trademark Office	Filing Date **herewith**	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Makris *et al., Female Mice Heterozygous for IKK-gamma/NEMO Deficiencies Develop a Dermatopathy Similar to the Human X-Linked Disorder Incontinentia Pigmenti, Molecular Cell*, **2000**, *5*:969-979
	AK	May *et al., Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex, Science*, **2000**, *289*:1550-1554
	AL	Mercurio *et al., IkappaB kinase (IKK)-associated protein 1, a common component of the heterogeneous IKK complex, Mol. Cell Biol.*, **1999**, *19*:1526-1538
	AM	O'Mahony *et al., Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions, Mol. Cell Biol.*, **2000**, *20*:1170-1178
	AN	Rothwarf *et al., IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex, Nature*, **1998**, *395*:297-300
	AO	Rudolph *et al., Severa Liver Degeneration and Lack of NF-kB Activation in NEMO/IKKg-deficient Mice, Genes & Development*, **2000**, *14*:854-862
	AP	Salmeron *et al., Direct phosphorylation of NF-kappaB1 p105 by the IkappaB kinase complex on serine 927 is essential for signal-induced p105 proteolysis, J. Biol. Chem.*, **2001**, *276*:22215-22222
	AQ	Schmidt-Supprian *et al., NEMO/IKKg-Deficient Mice Model Incontinentia Pigmenti, Molecular Cell*, **2000**, *5*:981-992
	AR	Smahi *et al., Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium, Nature*, **2000**, *405*:466-472
	AS	Yamaoka *et al., Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation, Cell*, **1998**, *93*:1231-1240

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0753	Serial No. not yet assigned
	Applicant Brett P. Monia *et al.*	
	Filing Date herewith	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AT	Zandi *et al.*, *Bridging the gap: composition, regulation, and physiological function of the IkappaB kinase complex*, *Mol. Cell Biol.*, **1999**, *19*:4547-4551
	AU	Zonana *et al.*, *A Novel X-linked Disorder of Immune Deficiency and Hypohidrotic Ectodermal Dysplasia Is Allelic to Incontinentia Pigmenti and Due to Mutations in IKK-gamma (NEMO)*, *American Journal of Human Genetics*, **2000**, *67*:1555-1562

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0753	Serial No.
	Applicant Brett P. Monia et al.	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES	Translation NO
	AO	WO99/47672	8-21-2001	PCT	X	
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER	DATE CONSIDERED

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. **ISPH-0753**	Serial No. **Not yet assigned**
	Applicant **Monia and Wyatt**	
	Filing Date **Herewith**	Group **Not yet assigned**

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
	BA	6,114,517	9-5-00	Monia et al.	536	24.5

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER	DATE CONSIDERED